Calcipotriene

Copenhagen, January 5, 2026 – MC2 Therapeutics, a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and dry and itchy skin announces today an agreement granting exclusive rights to Actor Pharmaceuticals Pty Ltd, to commercialize MC2’s Wynzora® Cream for the treatment of plaque psoriasis for adults in Australia. Wynzora® Cream was approved by The Australian Government Department of Health and Aged Care (Therapeutic Goods Administration) November 11, 2024, for topical treatment of mild to moderate plaque psoriasis on the body in adults and for treatment of scalp psoriasis. “Actor Pharmaceuticals is an Australian pharmaceutical company marketing innovative and branded pharmaceutical products. With Actor’s expertise, ambition and strategy to develop a meaningful dermatology portfolio, Actor is an excellent partner for MC2 to bring Wynzora® to Australian patients” said Trine Ahlgreen, Chief Executive Officer of MC2 Therapeutics. “This partnership supports our mission to make Wynzora® available to as many patients suffering from plaque psoriasis as possible.” “We look forward to working with MC2 to make Wynzora® Cream available to Australians who suffer from plaque psoriasis,” said Mark Jaggers, Chief Commercial Officer of Actor Pharmaceuticals. “Wynzora® Cream’s unique formulation and clinical profile will offer patients a new treatment option designed for effect and satisfaction in daily routines. Feedback from other countries where Wynzora® has been launched gives us confidence that Wynzora will also be welcomed by Australian patients.” About Wynzora® Cream Wynzora® Cream is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment for plaque psoriasis, including scalp psoriasis, in adults. Its dual mode of action is targeting the hallmark cytokines IL-23 and IL-17A/F immune axis and TNF-α expression in a single product. Wynzora® Cream is uniquely enabled by MC2’s formulation and drug delivery system PAD Technology™, allowing an effective convenient-to-use aqueous formulation. Wynzora® Cream was approved in the US by the FDA on July 20th, 2020, and in the first country in Europe on July 9th, 2021. About MC2 Therapeutics A/S MC2 Therapeutics is a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and dry and itchy skin through innovative and effective therapies. The company is dedicated to improving the lives of people with plaque psoriasis and inflamed dry and itchy skin through innovative and effective therapies and support. Wynzora® Cream is partnered with leading pharmaceutical companies specializing in dermatology covering more than 40 countries in four continents. The company is based in Hørsholm, Denmark and in Guildford, United Kingdom. For additional information on MC2 Therapeutics, please visit https://www.mc2therapeutics.com Contact: Trine Ahlgreen, +45 3150 5036, info@mc2therapeutics.com About Actor Pharmaceuticals PTY, LTD. Actor Pharmaceuticals., headquartered in Sydney, Australia, is a specialty pharmaceutical company focused on providing best-in-class pharmaceuticals, biosimilar medicines and over-the-counter products to healthcare professionals and consumers on the Australian and New Zealand market. For more information, visit www.actorpharma.com.au/ BACK

SUZHOU, China, Nov. 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced that the Company will present one of its autoimmune and inflammation pipeline assets, CS2015 (OX40L/TSLP bispecific antibody), in the format of an ePoster plus an on-site oral presentation at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). ACAAI is one of the most influential academic conferences in the fields of allergies, asthma, and immunology, attracting experts and scholars around the world to discuss the latest scientific advancements. This marks the first presentation of CS2015 at an international academic conference. The full content of the abstract and eposter is now officially available on the ACAAI website. Key highlights of the presentation: CS2015 features an asymmetric molecular design that simultaneously targets OX40L and TSLP, two clinically validated critical regulators of type 2 inflammation. The molecule incorporates an engineered Fc region with reduced binding affinity for FcγR, which extends its in vivo half-life and optimizes its pharmacokinetic (PK) profile to support long-term dosing intervals. CS2015 also exhibits excellent molecular stability, facilitating the development of high-concentration subcutaneous formulations. Its strong developability profile further supports high-yield and scalable manufacturing. 1. Dual Blockade: CS2015 lead molecule demonstrated potent inhibition of OX40L/OX40 and TSLP/TSLPR downstream signaling: CS2015 potently interrupted the engagement of hOX40L on hOX40 reporter cells and hTSLP on hTSLPR/IL-7Rα reporter cells, respectively; The blocking activities of CS2015 were comparable to those of benchmark (parental) antibodies, with single or sub nanomolar IC50s. 2. Robust Inhibition of Inflammatory Responses: CS2015 lead molecule inhibited the release of inflammatory cytokines from primary CD4+ T cells stimulated by TSLP/OX40L and suppressed TSLP-induced release of TARC (CCL17) in human monocytes and peripheral blood mononuclear cells (PBMC). 3. Early Signs of Efficacy: CS2015 demonstrated potent disease control activities in Atopic Dermatitis (AD) model with OX40 and TSLP humanized mice. In MC903-induced AD models, CS2015 lead molecule: Rapidly reduced skin lesion severity including ear and epidermal thickening; Decreased immune cells, especially mast cells infiltration; Reduced itch events. 4. Durability Advantage: CS2015 demonstrated superb PK profiles in Non-Human Primate (NHP), supporting long-term dosing intervals: CS2015 lead molecule K19LS exhibited a mean half-life of 21 days (504.6 hours, Subcutaneous [SC]) and 25.7 days (617.6 hours, Intravenous [IV]); K19LS had a clearance rate of 2.4 (SC) and 2.7 (IV) ml/day/kg, and was well-absorbed, with outstanding bioavailability. 5. Outstanding drug-like properties: Beyond the data shown in the poster, CS2015 further demonstrated: Outstanding accelerated stability under high-temperature stress (40°C); Low viscosity (scored at only 3.7 for a 100 mg/ml solution), promising for subcutaneous injection at high-concentration; Potent efficacy in the intranasal OVA/TSLP-induced asthma model by decreasing the secretion of IL-4, CCL17, IgE, etc., and alleviating pulmonary pathological changes. CStone will further advance the development of CS2015 to treat Th2 cell-mediated inflammation diseases, including AD, asthma, hidradenitis suppurativa (HS), chronic obstructive pulmonary disease (COPD), Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), etc. The presentation schedule is as follows: Title: CS2015 a TSLP/OX40L Bispecific Antibody as a Potential Novel Therapeutic Agent for Type 2 Inflammation Diseases Presentation Type: ePoster display & 15-min on-site oral presentation (ePoster ID: R377) Abstract ID: 8079 Date & Time: Friday, November 7, 3:05 PM ET Location: ePoster Area of the West Exhibit Hall, Monitor 22 *The abstract and ePoster have been officially available on ACAAI website: . About CStone CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas. Dedicated to addressing patients' unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications covering 9 indications. The company's pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit: . Forward-looking statements The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments. Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes. SOURCE CStone Pharmaceuticals 21% more press release views with Request a Demo